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Although RING-finger E3 ligases are instrumental in the regulation of inflammatory, 
apoptosis and cancer, their role in hepatocellular cancer (HCC) was unknown. We 
therefore analyzed the TCGA database 29 TGF-β pathway associated E3 ligases in 
HCC and identified mRNA alteration in 55% of the tumors, most prominently for UCHL5, 
PJA, WWP2, SMURF1/2 and KEAP1. We recently uncovered increased PJA1 
expression in TGF-β deficient (β2SP+/-/Smad3+/-) mice, which develop a human stem 
cell syndrome and HCC. Analyses of primary HCC datasets reveal increased PJA1 
correlates with decreased levels of TGF-β/Smad3 and their regulated genes including 
Smad9 and TGFBR3. PJA1 interacts with the Smad3 MH2 domain and β2SP N- and C-
terminal domains to promote ubiquitin-mediated Smad3 degradation in a TGF-β 
dependent manner. In addition, we found that PJA1 expression in HCC is negatively 
associated with the expression of c-FOS and SERPINE1. Overexpression of a RING-
domain-deleted PJA1 reduced HCC cell proliferation and PJA1 knockdown significantly 
decreased HCC anchorage-independent growth and tumorigenicity. E3 ligase inhibitors, 
RTA402/405, originally identified as inhibitors for KEAP1, blocking KEAP1-dependent 
Nrf2 ubiquitination was shown to inhibit HCC cell proliferation and tumor growth in nude 
mice. RTA402/405 increased β2SP and TGF-β signaling target expression and 
luciferase activity and RTA402 was shown to bind PJA1 RING-finger domain by 
molecular docking experiment. Finally, our results demonstrate that PJA1 promotes liver 
cancer stem cell formation in Smad3+/- mice. Taken together, these studies demonstrate 
that loss of β2SP and Smad3 through PJA1 could play an important role in the 
development of HCC and reveals that PJA1 may be novel therapeutic targets for this 
lethal disease. 
 
